In conclusion, the results from these studies implicate the ACOD1/itaconate pathway in the pathogenesis of SLE and its associated organ damage and indicate that strategies to target aberrant immunometabolism in autoimmunity could have positive therapeutic implications, including a potential role in decreasing organ damage in these devastating conditions. Here, ACOD1 is linked to Autoimmunity.